Dr. Kevin Williams is the Chief Medical Officer (CMO) for Pfizer Rare Disease. In this role, he leads a Medical Affairs organization of approximately 150 medical colleagues around the globe supporting Pfizer’s efforts and portfolio in Rare Disease.
#NNPA BlackPress

Diving into the Genetics of Sickle Cell Disease

NNPA NEWSWIRE — Research indicates that as many as 3 million Americans carry the sickle cell trait, primarily impacting African Americans. In fact, nearly 1 in 12 African Americans have the sickle cell trait. […read more]

Advertisements
Dr. Kevin Williams is the Chief Medical Officer (CMO) for Pfizer Rare Disease. In this role, he leads a Medical Affairs organization of approximately 150 medical colleagues around the globe supporting Pfizer’s efforts and portfolio in Rare Disease.
Commentary

ASK DR. KEVIN: Shedding Light on the “Invisible Symptoms” of Sickle Cell Disease

NNPA NEWSWIRE — What I’ve heard time and time again from people living with Sickle Cell Disease (SCD) is that they often feel isolated in their journey. Kyle, a patient living with SCD, recently summed it up nicely when he said, “Sometimes it is hard to just get out of bed. What it means to live in pain is not something that many can truly understand.” […read more]

Black History

PRESS ROOM: Pfizer and the National Newspaper Publishers Association Collaborate to Raise Awareness of Sickle Cell Disease and Need for Improved Patient Care

Media Contacts: Steven Danehy 212-733-1538 Steven.Danehy@pfizer.com Claudette Perry 212-588-8764 Ext. 2 cperry@nnpa.org Collaboration Aims to Educate on the Importance of Clinical Trials in Developing Potential New Sickle Cell Disease Therapies NEW YORK, NY, March 24, 2017 – Pfizer Inc. (NYSE:PFE) and the National Newspaper Publishers Read More

Health

For Diabetics, a New Insulin Inhaler Could Replace Shots as Early as 2014

[Business Week] The long promise of insulin that diabetics can inhale appears to be moving closer to the market. An inhalable insulin powder called Afrezza showed positive results for controlling diabetes in a late-stage clinical trial, the drug’s maker, MannKind (MNKD), reported today. Pharmaceutical companies have been Read More

Health

Rare Mutation Ignites Race for Cholesterol Drug

[New York Times] She was a 32-year-old aerobics instructor from a Dallas suburb — healthy, college educated, with two young children. Nothing out of the ordinary, except one thing. Her cholesterol was astoundingly low. Her low-density lipoprotein, or LDL, the form that promotes heart disease, Read More